Young Seob Kim

YH29407 with anti-PD-1 ameliorates anti-tumor effects via increased T cell functionality and antigen presenting machinery in the tumor microenvironment

S. Lim, B. Cho, J. Lee, 2022, Frontiers in Chemistry.

Clinical decision support algorithm based on machine learning to assess the clinical response to anti-programmed death-1 therapy in patients with non-small-cell lung cancer.

S. Heo, S. Lim, B. Cho, 2021, European journal of cancer.

Incorporation of SKI-G-801, a Novel AXL Inhibitor, With Anti-PD-1 Plus Chemotherapy Improves Anti-Tumor Activity and Survival by Enhancing T Cell Immunity

S. Heo, S. Lim, June-Dong Park, 2022, Frontiers in Oncology.

SKI‐G‐801, an AXL kinase inhibitor, blocks metastasis through inducing anti‐tumor immune responses and potentiates anti‐PD‐1 therapy in mouse cancer models

You Won Lee, S. Heo, S. Lim, 2021, Clinical & translational immunology.

Successful expansion and cryopreservation of human natural killer cell line NK-92 for clinical manufacturing

K. Pyo, Y. Byeon, Young Seob Kim, 2024, PloS one.

Exploration of Immune-Modulatory Effects of Amivantamab in Combination with Pembrolizumab in Lung and Head and Neck Squamous Cell Carcinoma

J. Curtin, K. Pyo, M. Yun, 2024, Cancer research communications.